Eczema Off-label Treatments
Filters
Age
Severity
Side Effects
Age
Eczema Severity Level
Max Side Effects Tolerated
Treatment
Who is this for?
Delivery
Effectiveness
Side Effects
Estimated Cost
-
HIGHEST EFFICACY IN CATEGORYCyclosporine(Cyclosporine)NoneIf other treatments don't work for you and you are looking for relief within 1-2 weeksOral dailyMedium
Side Effect Affected Liver and kidney toxicity Thrombotic Microangiopathy Serious infections KEY TAKEAWAYSCyclosporine works quickly (within 2-3 weeks) and is effective for treating severe atopic dermatitis in both adults and children, but is not recommended for use over one yearStudy Summary Study Type Studied Population Results 📄Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.Review Severity: moderate to severeAge: not availableHigh dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events. 📄Cyclosporine A was effective in treating severe atopic dermatitis in children, with 64% of patients showing good or excellent response after 4 weeks. Side effects were common but mild, and 20% of patients maintained improvement for more than 6 months after treatment.Observational Study Total Patients: 63Severity: severeAge: children (mean 8.4 years)Common side effects include kidney problems (nephrotoxicity), high blood pressure, increased risk of infections, gastrointestinal upset, and abnormal lab results. Children generally tolerate the medication better than adults.Study Summary Study Type Studied Population Results 📄Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.Review Severity: moderate to severeAge: not availableHigh dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events. 📄Cyclosporine A was effective in treating severe atopic dermatitis in children, with 64% of patients showing good or excellent response after 4 weeks. Side effects were common but mild, and 20% of patients maintained improvement for more than 6 months after treatment.Observational Study Total Patients: 63Severity: severeAge: children (mean 8.4 years)Studies show cyclosporine and dupilumab (a newer medication) are both effective treatments, with cyclosporine showing faster initial response but dupilumab potentially providing better long-term controlStudy Summary Study Type Studied Population Results 📄Both cyclosporine and methotrexate were effective in treating severe eczema in children and young people. Cyclosporine worked faster, but methotrexate's effects lasted longer after stopping treatment.Randomized Controlled Trial Total Patients: 103Severity: severeAge: 2-16 years📄This study compared two medications for moderate-to-severe eczema: dupilumab and cyclosporine. Dupilumab showed better results than cyclosporine in reducing eczema severity, both in the short term (12-16 weeks) and longer term (24-30 weeks). About 75-80% of patients on dupilumab had significant improvement compared to 40-56% on cyclosporine.Comparative Study Total Patients: 163Severity: moderate to severeAge: 18+Dupilumab showed consistently better results than cyclosporine in achieving 50% improvement in eczema severity Drug survival (how long patients stay on the medication) is about 1 year for cyclosporine, with most discontinuations due to either side effects or loss of effectivenessStudy Summary Study Type Studied Population Results 📄This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.Comparative Study Total Patients: 94Severity: moderate to severeAge: 18+📄Patients with moderate to severe atopic dermatitis stayed on cyclosporine treatment for about 1 year on average. This duration was longer than in patients with psoriasis, who stayed on the medication for about 4.4 months.Multicenter Study Total Patients: 130Severity: moderate to severeAge: not availablePatients with atopic dermatitis stayed on cyclosporine treatment longer than patients with psoriasis -
HIGHEST EFFICACY IN CATEGORYCyclosporine (Cyclosporine)Who is this for?:If other treatments don't work for you and you are looking for relief within 1-2 weeksNoneEffectiveness:Side Effects:MediumCost:Delivery:Oral dailySee EvidenceGet This TreatmentKEY TAKEAWAYS
Cyclosporine works quickly (within 2-3 weeks) and is effective for treating severe atopic dermatitis in both adults and children, but is not recommended for use over one year
Summary:Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.Study Type:ReviewStudied Population:Severity: moderate to severeAge: not availableResults:High dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events.
Summary:Cyclosporine A was effective in treating severe atopic dermatitis in children, with 64% of patients showing good or excellent response after 4 weeks. Side effects were common but mild, and 20% of patients maintained improvement for more than 6 months after treatment.Study Type:Observational StudyStudied Population:Total Patients: 63Severity: severeAge: children (mean 8.4 years)Results:
Common side effects include kidney problems (nephrotoxicity), high blood pressure, increased risk of infections, gastrointestinal upset, and abnormal lab results. Children generally tolerate the medication better than adults.
Summary:Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.Study Type:ReviewStudied Population:Severity: moderate to severeAge: not availableResults:High dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events.
Summary:Cyclosporine A was effective in treating severe atopic dermatitis in children, with 64% of patients showing good or excellent response after 4 weeks. Side effects were common but mild, and 20% of patients maintained improvement for more than 6 months after treatment.Study Type:Observational StudyStudied Population:Total Patients: 63Severity: severeAge: children (mean 8.4 years)Results:
Studies show cyclosporine and dupilumab (a newer medication) are both effective treatments, with cyclosporine showing faster initial response but dupilumab potentially providing better long-term control
Summary:Both cyclosporine and methotrexate were effective in treating severe eczema in children and young people. Cyclosporine worked faster, but methotrexate's effects lasted longer after stopping treatment.Study Type:Randomized Controlled TrialStudied Population:Total Patients: 103Severity: severeAge: 2-16 yearsResults:
Summary:This study compared two medications for moderate-to-severe eczema: dupilumab and cyclosporine. Dupilumab showed better results than cyclosporine in reducing eczema severity, both in the short term (12-16 weeks) and longer term (24-30 weeks). About 75-80% of patients on dupilumab had significant improvement compared to 40-56% on cyclosporine.Study Type:Comparative StudyStudied Population:Total Patients: 163Severity: moderate to severeAge: 18+Results:Dupilumab showed consistently better results than cyclosporine in achieving 50% improvement in eczema severity
Drug survival (how long patients stay on the medication) is about 1 year for cyclosporine, with most discontinuations due to either side effects or loss of effectiveness
Summary:This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.Study Type:Comparative StudyStudied Population:Total Patients: 94Severity: moderate to severeAge: 18+Results:
Summary:Patients with moderate to severe atopic dermatitis stayed on cyclosporine treatment for about 1 year on average. This duration was longer than in patients with psoriasis, who stayed on the medication for about 4.4 months.Study Type:Multicenter StudyStudied Population:Total Patients: 130Severity: moderate to severeAge: not availableResults:Patients with atopic dermatitis stayed on cyclosporine treatment longer than patients with psoriasis
-
CellCept(Mycophenolate mofetil)If your child has have widespread severe flareups and topicals don't workIf you have widespread flareups and topicals don't work for youOral dailyHigh
Side Effect Affected Diarrhea 45% Leukopenia 36% Bacterial infections 34% Viral infections 31% KEY TAKEAWAYSMycophenolate mofetil has shown good efficacy for treating atopic dermatitis, with studies showing that about 78% of patients achieve partial or full remission of symptoms. It works by suppressing the immune system and typically takes 6-8 weeks to show effects.Study Summary Study Type Studied Population Results 📄This study looked at 10 years of data on oral immunosuppressive treatments for severe atopic dermatitis in two hospitals. Cyclosporine A was the most commonly used medication (80% of patients), followed by mycophenolate mofetil (31%). Treatment was often stopped due to either the disease being controlled, the medication not working, or side effects.Multicenter Study Total Patients: 334Severity: severeAge: 18+The medication is generally considered safe but requires monitoring. Common side effects include headaches, herpes infections, stomach upset, liver function abnormalities, and reduced blood cell counts. There is also a small risk of developing infections or cancer due to the immune suppression.Study Summary Study Type Studied Population Results 📄This real-world study looked at side effects of various medications used to treat atopic dermatitis, including dupilumab and other immunomodulating drugs. The study found some side effects occurred more frequently than expected, particularly eye-related issues and facial redness with dupilumab, and fatigue with methotrexate.Observational Study Total Patients: 266Severity: not availableAge: adults and pediatric patients📄This study looked at 10 years of data on oral immunosuppressive treatments for severe atopic dermatitis in two hospitals. Cyclosporine A was the most commonly used medication (80% of patients), followed by mycophenolate mofetil (31%). Treatment was often stopped due to either the disease being controlled, the medication not working, or side effects.Multicenter Study Total Patients: 334Severity: severeAge: 18+In rare cases, serious complications can occur. One reported case showed development of Candida infection in the esophagus after 22 months of treatment. Another case reported development of lung disease, though this resolved after stopping the medication.Study Summary Study Type Studied Population Results 📄A patient treated with mycophenolate mofetil (MMF) for atopic dermatitis developed a fungal infection in their esophagus after 22 months of treatment. This is a rare complication that hasn't been reported before with MMF treatment.Case Reports Total Patients: 1Severity: not availableAge: 59📄A patient with severe atopic dermatitis was treated with mycophenolate mofetil (MMF) and developed lung problems (interstitial lung disease) as a side effect. After stopping MMF and receiving steroid treatment, the patient's lung condition improved.Case Reports Total Patients: 1Severity: severeAge: 37 yearsMMF showed good clinical effect but had to be discontinued due to serious side effects When compared to other treatments, mycophenolate mofetil appears to have lower effectiveness than newer medications like dupilumab. However, it may still be a useful option for some patients, particularly when other treatments have failed or aren't suitable.Study Summary Study Type Studied Population Results 📄This real-world study compared the safety of dupilumab to conventional systemic treatments for atopic dermatitis over 5 years. Dupilumab showed fewer side effects related to circulatory, respiratory, and musculoskeletal systems, and infections compared to other treatments. However, it did have a higher risk of eye inflammation (conjunctivitis) compared to some other medications.Comparative Study 📄This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.Comparative Study Total Patients: 94Severity: moderate to severeAge: 18+ -
CellCept (Mycophenolate mofetil)Who is this for?:If you have widespread flareups and topicals don't work for youIf your child has have widespread severe flareups and topicals don't workEffectiveness:Side Effects:HighCost:Delivery:Oral dailySee EvidenceGet This TreatmentKEY TAKEAWAYS
Mycophenolate mofetil has shown good efficacy for treating atopic dermatitis, with studies showing that about 78% of patients achieve partial or full remission of symptoms. It works by suppressing the immune system and typically takes 6-8 weeks to show effects.
Summary:This study looked at 10 years of data on oral immunosuppressive treatments for severe atopic dermatitis in two hospitals. Cyclosporine A was the most commonly used medication (80% of patients), followed by mycophenolate mofetil (31%). Treatment was often stopped due to either the disease being controlled, the medication not working, or side effects.Study Type:Multicenter StudyStudied Population:Total Patients: 334Severity: severeAge: 18+Results:
The medication is generally considered safe but requires monitoring. Common side effects include headaches, herpes infections, stomach upset, liver function abnormalities, and reduced blood cell counts. There is also a small risk of developing infections or cancer due to the immune suppression.
Summary:This real-world study looked at side effects of various medications used to treat atopic dermatitis, including dupilumab and other immunomodulating drugs. The study found some side effects occurred more frequently than expected, particularly eye-related issues and facial redness with dupilumab, and fatigue with methotrexate.Study Type:Observational StudyStudied Population:Total Patients: 266Severity: not availableAge: adults and pediatric patientsResults:
Summary:This study looked at 10 years of data on oral immunosuppressive treatments for severe atopic dermatitis in two hospitals. Cyclosporine A was the most commonly used medication (80% of patients), followed by mycophenolate mofetil (31%). Treatment was often stopped due to either the disease being controlled, the medication not working, or side effects.Study Type:Multicenter StudyStudied Population:Total Patients: 334Severity: severeAge: 18+Results:
In rare cases, serious complications can occur. One reported case showed development of Candida infection in the esophagus after 22 months of treatment. Another case reported development of lung disease, though this resolved after stopping the medication.
Summary:A patient treated with mycophenolate mofetil (MMF) for atopic dermatitis developed a fungal infection in their esophagus after 22 months of treatment. This is a rare complication that hasn't been reported before with MMF treatment.Study Type:Case ReportsStudied Population:Total Patients: 1Severity: not availableAge: 59Results:
Summary:A patient with severe atopic dermatitis was treated with mycophenolate mofetil (MMF) and developed lung problems (interstitial lung disease) as a side effect. After stopping MMF and receiving steroid treatment, the patient's lung condition improved.Study Type:Case ReportsStudied Population:Total Patients: 1Severity: severeAge: 37 yearsResults:MMF showed good clinical effect but had to be discontinued due to serious side effects
When compared to other treatments, mycophenolate mofetil appears to have lower effectiveness than newer medications like dupilumab. However, it may still be a useful option for some patients, particularly when other treatments have failed or aren't suitable.
Summary:This real-world study compared the safety of dupilumab to conventional systemic treatments for atopic dermatitis over 5 years. Dupilumab showed fewer side effects related to circulatory, respiratory, and musculoskeletal systems, and infections compared to other treatments. However, it did have a higher risk of eye inflammation (conjunctivitis) compared to some other medications.Study Type:Comparative StudyStudied Population:Results:
Summary:This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.Study Type:Comparative StudyStudied Population:Total Patients: 94Severity: moderate to severeAge: 18+Results:
Other Off-label Treatments
Treatment
Who is this for?
Delivery
Effectiveness
Side Effects
Estimated Cost
-
Methotrexate(Methotrexate)NoneIf you have severe eczema that affects a large part of your body and doesn't respond well to steroidsOral or injection dailyHigh
Side Effect Affected Elevated liver tests 15% Nausea/vomiting 10% Stomatitis 3% Thrombocytopenia 3% KEY TAKEAWAYSMethotrexate is slower to work but can be effective for long-term control of atopic dermatitis. It typically takes at least 6 weeks to see effects. The medication works by decreasing inflammation through inhibiting cell division and lymphocyte proliferation.Study Summary Study Type Studied Population Results 📄Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.Review Severity: moderate to severeAge: not availableHigh dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events. 📄This study compared two medications for moderate-to-severe eczema: methotrexate and cyclosporine. While cyclosporine worked better at 8 weeks, increasing the dose of methotrexate led to similar effectiveness by 20 weeks. Cyclosporine had more side effects than methotrexate.Clinical Trial Total Patients: 97Cyclosporine was more effective than methotrexate at 8 weeks Common side effects include nausea, vomiting, diarrhea, and fatigue. More serious but rare side effects include liver toxicity and low blood counts, which requires regular blood test monitoring. Taking folic acid supplements helps reduce these side effects.Study Summary Study Type Studied Population Results 📄Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.Review Severity: moderate to severeAge: not availableHigh dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events. When compared to other treatments, methotrexate shows lower effectiveness than cyclosporine and dupilumab in the short term (8 weeks), but may have better long-term outcomes. In children, methotrexate shows better drug survival rates than cyclosporine but lower than dupilumab.Study Summary Study Type Studied Population Results 📄This study compared two medications for moderate-to-severe eczema: methotrexate and cyclosporine. While cyclosporine worked better at 8 weeks, increasing the dose of methotrexate led to similar effectiveness by 20 weeks. Cyclosporine had more side effects than methotrexate.Clinical Trial Total Patients: 97Cyclosporine was more effective than methotrexate at 8 weeks 📄This study compared how long children with severe eczema stayed on different medications (dupilumab, methotrexate, and cyclosporine). Dupilumab showed the best long-term results, with 84% of patients still using it after 1 year, compared to 61% for methotrexate and 44% for cyclosporine. The main reasons patients stopped treatments were because they weren't working well enough or because of side effects.Comparative Study Total Patients: 362Severity: moderate to severeAge: 2-17 yearsDupilumab showed consistently better long-term continuation rates compared to methotrexate and cyclosporine The medication can be used as a maintenance therapy for longer-term control of atopic dermatitis, unlike cyclosporine which is typically limited to one year of use due to side effects.Study Summary Study Type Studied Population Results 📄Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.Review Severity: moderate to severeAge: not availableHigh dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events. 📄Both cyclosporine and methotrexate were effective in treating severe eczema in children and young people. Cyclosporine worked faster, but methotrexate's effects lasted longer after stopping treatment.Randomized Controlled Trial Total Patients: 103Severity: severeAge: 2-16 years -
Methotrexate (Methotrexate)Who is this for?:If you have severe eczema that affects a large part of your body and doesn't respond well to steroidsNoneEffectiveness:Side Effects:HighCost:Delivery:Oral or injection dailySee EvidenceGet This TreatmentKEY TAKEAWAYS
Methotrexate is slower to work but can be effective for long-term control of atopic dermatitis. It typically takes at least 6 weeks to see effects. The medication works by decreasing inflammation through inhibiting cell division and lymphocyte proliferation.
Common side effects include nausea, vomiting, diarrhea, and fatigue. More serious but rare side effects include liver toxicity and low blood counts, which requires regular blood test monitoring. Taking folic acid supplements helps reduce these side effects.
When compared to other treatments, methotrexate shows lower effectiveness than cyclosporine and dupilumab in the short term (8 weeks), but may have better long-term outcomes. In children, methotrexate shows better drug survival rates than cyclosporine but lower than dupilumab.
The medication can be used as a maintenance therapy for longer-term control of atopic dermatitis, unlike cyclosporine which is typically limited to one year of use due to side effects.
-
Olumiant(Baricitinib)If your child is over 2 years old, needs strong and fast relieve, and treatments applied to the skin are not sufficient or appropriateIf you need strong and fast relieve and treatments applied to the skin are not sufficient or appropriateOral once dailyMedium
Side Effect Affected Nasopharyngitis 12% Upper respiratory tract infection 8% Folliculitis 6% Pulmonary embolism 1% KEY TAKEAWAYSBaricitinib 4mg combined with topical corticosteroids (TCS) is effective for treating moderate-to-severe atopic dermatitis, with about 31% of patients achieving clear or almost clear skin after 16 weeks of treatment. The medication starts working quickly, with improvements in itch seen as early as 2-4 days after starting treatment.Study Summary Study Type Studied Population Results 📄Baricitinib 4mg combined with topical steroids helped improve moderate-to-severe atopic dermatitis symptoms in adults after 16 weeks of treatment. About 48% of patients on 4mg baricitinib achieved a 75% improvement in their eczema severity score (EASI-75), compared to 23% on placebo. The medication also helped reduce itch quickly, with improvements seen as early as 2 days after starting treatment.Clinical Trial Total Patients: 329📄Baricitinib, whether used alone or with topical steroids, quickly improved all four main signs of eczema (excoriation, swelling/bumps, redness, and skin thickening). The medication worked particularly well for reducing scratching damage, with improvements seen as early as the first week of treatment.Randomized Controlled Trial Severity: moderate to severeAge: adultsBaricitinib improved all signs of eczema, with particularly rapid effects on scratching damage The benefits of baricitinib can be maintained long-term (up to 52-68 weeks) in patients who respond to treatment. Some patients can even reduce their dose while maintaining benefits, though others may need to continue the original dose.Study Summary Study Type Studied Population Results 📄Baricitinib is effective in treating moderate-to-severe atopic dermatitis in adults. Clinical trials showed that it can significantly improve skin clearance and reduce itch, with about 30-40% of patients achieving clear or almost clear skin after 16 weeks of treatment.Randomized Controlled Trial Severity: moderate to severeAge: 18+Baricitinib 4mg showed the best results for skin clearance 📄This study looked at what happens when patients who responded well to baricitinib either continued their dose, reduced their dose, or stopped treatment completely. Most patients who reduced their dose maintained improvement in their eczema, and those who lost improvement usually got better again when restarting their original dose.Clinical Trial Total Patients: 526Severity: moderate to severeAge: not availableMost patients who lost response regained improvement after restarting their original dose 📄Baricitinib combined with topical steroids showed long-term effectiveness in treating moderate-to-severe eczema for up to 68 weeks. About 40-60% of patients saw significant improvement in their eczema symptoms, and around 40-50% experienced meaningful itch reduction.Clinical Trial Total Patients: 155Severity: moderate to severeAge: 18+Long-term improvement in eczema severity was maintained across both doses Common side effects include nasopharyngitis (common cold), herpes simplex infections, upper respiratory infections, and headache. While the medication is generally well-tolerated, patients need to be monitored for infections and other potential side effects.Study Summary Study Type Studied Population Results 📄Baricitinib 4mg combined with topical steroids helped improve moderate-to-severe atopic dermatitis symptoms in adults after 16 weeks of treatment. About 48% of patients on 4mg baricitinib achieved a 75% improvement in their eczema severity score (EASI-75), compared to 23% on placebo. The medication also helped reduce itch quickly, with improvements seen as early as 2 days after starting treatment.Clinical Trial Total Patients: 329📄Baricitinib combined with topical steroids was effective in treating moderate-to-severe eczema in patients who couldn't use or didn't respond to ciclosporin. After 16 weeks, 32% of patients on the highest dose (4mg) had their eczema improve by 75% or more, compared to 17% on placebo, and these improvements lasted for up to one year.Clinical Trial Total Patients: 463Severity: moderate to severeAge: not availableIn real-world clinical practice, about 43% of patients may discontinue treatment due to lack of effectiveness or side effects. However, the medication can be effective even in patients who didn't respond to other treatments like dupilumab.Study Summary Study Type Studied Population Results 📄Baricitinib showed some effectiveness in treating difficult-to-treat eczema patients, including those who didn't respond to dupilumab. However, about 43% of patients stopped treatment due to either lack of effectiveness or side effects. The most common side effects were nausea, urinary tract infections, and herpes simplex infections.Multicenter Study Total Patients: 51Severity: moderate to severeAge: 18+About 3 in 10 patients achieved low disease activity after 16 weeks -
Olumiant (Baricitinib)Who is this for?:If you need strong and fast relieve and treatments applied to the skin are not sufficient or appropriateIf your child is over 2 years old, needs strong and fast relieve, and treatments applied to the skin are not sufficient or appropriateEffectiveness:Side Effects:MediumCost:Delivery:Oral once dailySee EvidenceGet This TreatmentKEY TAKEAWAYS
Baricitinib 4mg combined with topical corticosteroids (TCS) is effective for treating moderate-to-severe atopic dermatitis, with about 31% of patients achieving clear or almost clear skin after 16 weeks of treatment. The medication starts working quickly, with improvements in itch seen as early as 2-4 days after starting treatment.
The benefits of baricitinib can be maintained long-term (up to 52-68 weeks) in patients who respond to treatment. Some patients can even reduce their dose while maintaining benefits, though others may need to continue the original dose.
Common side effects include nasopharyngitis (common cold), herpes simplex infections, upper respiratory infections, and headache. While the medication is generally well-tolerated, patients need to be monitored for infections and other potential side effects.
In real-world clinical practice, about 43% of patients may discontinue treatment due to lack of effectiveness or side effects. However, the medication can be effective even in patients who didn't respond to other treatments like dupilumab.
-
Imuran(Azathioprine)NoneIf you have severe eczema but can wait 2-3 months for a responseOral dailyHigh
Side Effect Affected Leukopenia (any degree) 28% Severe Leukopenia (<2,500 cells/mm3) 5% Infections 1% Nausea and vomiting 12% KEY TAKEAWAYSAzathioprine has shown lower effectiveness compared to newer treatments like dupilumab and high-dose cyclosporine for treating moderate-to-severe atopic dermatitis.Study Summary Study Type Studied Population Results 📄Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.Review Severity: moderate to severeAge: not availableHigh dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events. Azathioprine has a slow onset of action (taking weeks to months to work) and requires regular blood test monitoring due to potential side effects on bone marrow and liver.Study Summary Study Type Studied Population Results 📄Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.Review Severity: moderate to severeAge: not availableHigh dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events. Common side effects include stomach upset, increased risk of infections and cancers, bone marrow suppression, liver toxicity, and rare allergic reactions. Due to these risks, recent medical guidelines recommend against using azathioprine for atopic dermatitis.Study Summary Study Type Studied Population Results 📄Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.Review Severity: moderate to severeAge: not availableHigh dose cyclosporine and dupilumab showed superior efficacy compared to methotrexate and azathioprine. High-dose upadacitinib showed highest efficacy but with more adverse events. 📄This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.Comparative Study Total Patients: 94Severity: moderate to severeAge: 18+Treatment discontinuation rates are high with azathioprine, mainly due to side effects and lack of effectiveness. Studies show it has a higher rate of discontinuation compared to other treatments like dupilumab.Study Summary Study Type Studied Population Results 📄This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.Comparative Study Total Patients: 94Severity: moderate to severeAge: 18+📄This study looked at 10 years of data on oral immunosuppressive treatments for severe atopic dermatitis in two hospitals. Cyclosporine A was the most commonly used medication (80% of patients), followed by mycophenolate mofetil (31%). Treatment was often stopped due to either the disease being controlled, the medication not working, or side effects.Multicenter Study Total Patients: 334Severity: severeAge: 18+ -
Imuran (Azathioprine)Who is this for?:If you have severe eczema but can wait 2-3 months for a responseNoneEffectiveness:Side Effects:HighCost:Delivery:Oral dailySee EvidenceGet This TreatmentKEY TAKEAWAYS
Azathioprine has shown lower effectiveness compared to newer treatments like dupilumab and high-dose cyclosporine for treating moderate-to-severe atopic dermatitis.
Azathioprine has a slow onset of action (taking weeks to months to work) and requires regular blood test monitoring due to potential side effects on bone marrow and liver.
Common side effects include stomach upset, increased risk of infections and cancers, bone marrow suppression, liver toxicity, and rare allergic reactions. Due to these risks, recent medical guidelines recommend against using azathioprine for atopic dermatitis.
Treatment discontinuation rates are high with azathioprine, mainly due to side effects and lack of effectiveness. Studies show it has a higher rate of discontinuation compared to other treatments like dupilumab.
Eczema is more than skin deep
Join our waitlist while we set up personalized holistic eczema care.
Choose Your Preferences to Optimize Your Treatment
Age
Eczema Severity Level
Max Side Effects Tolerated
Insurance Coverage
Include Steroidal Creams